## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.6% in lower entry zone (3.0-6.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+1.8% 5-day acceleration). Outperforming sector by 3.8%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($48.36)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates**
- Source: Insider Monkey | 20251203T015700 | Somewhat-Bullish | Relevance: 99%
- Cantor Fitzgerald maintained its Neutral rating and $45 price target on Bristol-Myers Squibb (BMY) after new data bolstered confidence in the company's milvexian SSP program. The firm described the update as a "needed win" following previous setbacks, anticipating a positive reset in sentiment around milvexian. However, the sustainability of this sentiment is contingent on future data outcomes, particularly from the Cobenfy ADEPT-2 trial.

**2. Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb**
- Source: Yahoo Finance | 20251203T160000 | Bullish | Relevance: 99%
- Terray Therapeutics announced the achievement of a drug discovery milestone in its multi-target collaboration with Bristol Myers Squibb. This success highlights the effectiveness of Terray's proprietary AI platform, EMMI, which integrates high-throughput experimentation, a vast target-ligand binding database, and generative AI to discover and optimize novel molecules for complex drug targets. The collaboration aims to accelerate small molecule drug discovery for areas with significant unmet medical needs.

**3. Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast**
- Source: ts2.tech | 20251202T032425 | Neutral | Relevance: 99%
- Bristol-Myers Squibb (BMY) is navigating significant developments in December 2025, including a $6.7 billion Celgene CVR lawsuit moving forward and positive momentum from its cell therapy Breyanzi with new EU approvals and promising ASH 2025 hematology data. The article also discusses a milvexian setback, strategic partnerships, strong Q3 2025 results, and a pipeline of 48 compounds, evaluating BMY's stock as a "Hold" due to its high dividend yield and value profile balanced against patent cliffs and legal risks.

**4. Round Hill Asset Management Has $2.12 Million Stock Holdings in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251202T125827 | Neutral | Relevance: 99%
- Round Hill Asset Management significantly increased its stake in Bristol Myers Squibb (NYSE:BMY) by 191.2% in Q2, now holding 45,717 shares valued at $2.12 million. The article also notes an insider sale by EVP David V. Elkins and provides an overview of Bristol Myers Squibb's financial performance, analyst ratings, and dividend information.

**5. Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio**
- Source: BioSpace | 20251202T100551 | Bullish | Relevance: 99%
- Bristol Myers Squibb (NYSE: BMY) announced the presentation of more than 95 data disclosures, including 27 oral presentations, at the 67th American Society of Hematology (ASH) Annual Meeting. The data highlight advancements in the companyâ€™s next-generation hematology portfolio, focusing on targeted protein degradation and cell therapy research platforms across multiple myeloma, lymphomas, and myeloid diseases. Key presentations include promising results for iberdomide in newly diagnosed multiple myeloma, golcadomide in lymphoma, a novel BCL6 degrader in NHL, and long-term Breyanzi data in LBCL and FL.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (2 raises, avg +15%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.1B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.5 |
| Current P/E | 7.8 |
| YoY Growth | -8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.8% to 3.6% (+1.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 85th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.57% (CS: 85) | Strong |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.067x | Above |
| vs SMA50 | 1.113x | Above |
| vs SMA200 | 1.038x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $50.96
- **Stop Loss:** $48.36 (5.1% risk)
- **Target:** $54.86 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 365
- **Position Value:** $18,600.40
- **Portfolio %:** 18.60%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*